Log in to your Inderes Free account to see all free content on this page.
Genovis
24.55
SEK
-1.6 %
GENO
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1,661 following
-1.6%
-12.48%
+5.82%
-14.76%
-52.79%
-51.1%
-62.92%
-2.58%
-10.33%
Genovis is active in biotechnology. The greatest focus in the business is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to make it easier for the LifeScience industry to conduct preclinical research. The company's products are resold under a number of brands. Genovis was established in 1999 and is headquartered in Lund.
Read moreMarket cap
1.61B SEK
Turnover
1.01M SEK
Revenue
EBIT %
P/E
Dividend yield-%
Financial calendar
14.2.
2025
Annual report '24
21.5.
2025
Interim report Q1'25
12.8.
2025
Interim report Q2'25
ShowingAll content types
Genovis AB: Interim Report January-September 2024
Genovis AB: Genovis Launches FabRICATOR® Xtra: Next-Generation Enzyme for Future Antibody Therapeutics
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio